Cancer Center, The People's Hospital of Guangxi Zhuang Autonomous Region, China.
Medicine (Baltimore). 2021 Mar 26;100(12):e25218. doi: 10.1097/MD.0000000000025218.
The relation between the expression of macrophage-colony stimulating factor-1 receptor (CSF-1R) and prognosis of cancer patients has been evaluated in multiple studies, but the results remain controversial. We, therefore, performed a meta-analysis and systematic review to figure out the role of CSF-1R in the prognosis of patients with cancer.
Several databases were searched, including Web of Science, PubMed, and EMBASE. All human studies were published as full text. The Newcastle-Ottawa risk of bias scale was applied to evaluate the research. We extracted hazard ratios (HRs) with 95% confidence interval (95% CI) which assessed progression-free survival (PFS) and overall survival (OS) in order to assess the impacts of CSF-1R on the prognosis of cancer patients.
A total of 12 citations were identified, with studies including 2260 patients in different cancer types that met the eligibility criteria. It was suggested in a pooled analysis that the over-expression of CSF-1R was significantly related to worse PFS (HR: 1.68; P < .001, 1.25-2.10, 95% CI) and also poorer OS (HR=1.28; P < .001, 1.03-1.54, 95% CI). Analysis in subgroups indicated over-expressed CSF-1R was significantly associated with worse OS in hematological malignancy (HR = 2.29; P < .001, 1.49-3.09, 95% CI; model of fixed-effects; I2 = 0.0%, P < .001). Sensitivity analysis suggested that there was no study influencing the stability of the results.
The overexpression of CSF-1R was significantly predictive of worse prognosis in those who suffer from different kinds of malignancies, particularly in hematological malignancy, which indicates that it might be a potential biomarker of prognosis in cancer survival and a potential molecular target in the treatment of malignant tumors.
巨噬细胞集落刺激因子-1 受体（CSF-1R）的表达与癌症患者的预后之间的关系已在多项研究中进行了评估，但结果仍存在争议。因此，我们进行了荟萃分析和系统评价，以确定 CSF-1R 在癌症患者预后中的作用。
我们搜索了多个数据库，包括 Web of Science、PubMed 和 EMBASE。所有人类研究均以全文发表。应用纽卡斯尔-渥太华偏倚风险量表评估研究。我们提取风险比（HR）及其 95%置信区间（95%CI），以评估 CSF-1R 对癌症患者预后的影响，这些 HR 用于评估无进展生存期（PFS）和总生存期（OS）。
共确定了 12 项引文，其中包括符合纳入标准的不同癌症类型的 2260 名患者的研究。荟萃分析表明，CSF-1R 的过度表达与较差的 PFS（HR：1.68；P<0.001，1.25-2.10，95%CI）和较差的 OS（HR=1.28；P<0.001，1.03-1.54，95%CI）显著相关。亚组分析表明，CSF-1R 过度表达与血液恶性肿瘤患者的 OS 较差显著相关（HR=2.29；P<0.001，1.49-3.09，95%CI；固定效应模型；I2=0.0%，P<0.001）。敏感性分析表明，没有研究影响结果的稳定性。
CSF-1R 的过度表达与不同类型恶性肿瘤患者的预后较差显著相关，特别是在血液恶性肿瘤中，这表明它可能是癌症生存中预后的潜在生物标志物和恶性肿瘤治疗中的潜在分子靶点。
